DRAM1 Antibody

• Catalog Number: orb1239379
• Category: Antibodies
• Description: DRAM1 Antibody
• Species/Host: Rabbit
• Clonality: Polyclonal
• Tested applications: ELISA, IF, IHC-P, WB
• Reactivity: Human, Mouse, Rat
• Isotype: IgG
• Immunogen: Anti-DRAM antibody (orb1239379) was raised against a peptide corresponding to 16 amino acids near the carboxy terminus of human DRAM. The immunogen is located within amino acids 170-220 of DRAM.
• Concentration: 1 mg/mL
• Dilution range: WB: 1 μg/mL; IF: 20 μg/mL; IHC: 2.5 μg/mL.Antibody validated: Western Blot in human, mouse and rat samples, Immunofluorescence and Immunohistochemistry in human samples. All other applications and species not yet tested.
• Form/Appearance: Liquid
• Conjugation: Unconjugated
• MW: Predicted: 14kD, 26kDObserved: 14 kD, 26kD
• Target: DRAM1
• UniProt ID: Q8N682
• NCBI: AAH18435
• Storage: DRAM antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
• Buffer/Preservatives: DRAM Antibody is supplied in PBS containing 0.02% sodium azide.
• Alternative names: DRAM Antibody: DRAM, DRAM, DNA damage-regulated au
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: DRAM orb1239379 (0.5 µg/mL), DRAM orb1239371 (2 µg/mL), beta-actin (1 µg/mL) and GAPDH (0.02 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Immunofluorescence Validation of DRAM in Human Liver Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed human liver tissue labeling DRAM with orb1239379 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Immunohistochemistry Validation of DRAM in Human Liver Tissue. Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-DRAM antibody (orb1239379) at 2.5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Induced Expression of DRAM by CQ in Mouse Neural Precursor Cells (NPCs) (Walls et al., 2010). WT and p53-deficient NPC cells were treated with or without 25µM CQ for 24hr. CQ treatment caused the increased expression level in both DRAM dimer (32kD) and monomer (16kD) compared to the untreated controls. WB results show DRAM induction was p53-dependent.

Regulated Expression Validation of DRAM in Heterozygous SOD2 KO Mice (Mehta et al., 2011). DRAM expression level detected by anti-DRAM antibodies (orb1239379) decreased in striatum of SOD -/+ KO mice (fig. d) as compared to WT mice.